Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) have been given a consensus rating of “Moderate Buy” by the seven brokerages that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company.

A number of research analysts have commented on BAYRY shares. DZ Bank upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 19th. Jefferies Financial Group upgraded shares of Bayer Aktiengesellschaft to a “hold” rating in a research note on Friday, May 29th. Zacks Research upgraded shares of Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a research note on Friday, May 8th. Finally, UBS Group upgraded shares of Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a research note on Monday, March 16th.

Bayer Aktiengesellschaft Price Performance

BAYRY opened at $10.56 on Friday. The company has a fifty day simple moving average of $10.97 and a 200 day simple moving average of $11.42. The firm has a market cap of $41.51 billion, a price-to-earnings ratio of -16.50, a PEG ratio of 3.39 and a beta of 0.59. Bayer Aktiengesellschaft has a twelve month low of $7.19 and a twelve month high of $14.85. The company has a current ratio of 1.05, a quick ratio of 0.63 and a debt-to-equity ratio of 1.06.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last released its quarterly earnings results on Tuesday, May 12th. The company reported $0.79 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.15. The business had revenue of $15.73 billion during the quarter, compared to analyst estimates of $15.77 billion. Bayer Aktiengesellschaft had a negative net margin of 4.75% and a positive return on equity of 17.61%. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. Equities research analysts expect that Bayer Aktiengesellschaft will post 1.25 EPS for the current fiscal year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.